Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cambridge Health Alliance
With
Emory University
GlaxoSmithKline
This study is 8 weeks long, with an optional additional 8 weeks. The study is placebo-controlled and patients are randomized to receive either ropinerol or placebo. Changes in depression, anxiety and overall psychiatric symptoms will be monitored during participation.
Age
18–64
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Meet DSM-IV criteria for bipolar disorder
Current MADRS score \> 16
Current MRS-SADS score \< 10
Prior to participation in this study, each subject must sign an informed consent.
You may not be if
Any serious acute medical illness
Any clinically serious evidence of suicidality or score of 3 or greater on suicide item on MADRS scale
Clareo Health | Ropinirole in the Treatment of Bipolar Depression
